Detailed explanation of the role and efficacy of pemetinib/pemetinib

Pemigatinib(Pemigatinib) is an oral drug that belongs to a class of drugs called tyrosine kinasesInhibitors drugs. It is mainly used to treat a malignant tumor called FGFR variant cholangiocarcinoma (CCA). Pemetinib inhibits a protein called fibroblast growth factor receptor (FGFR), which is overactive in some cholangiocarcinoma cells. By inhibiting FGFR, pemetinib blocks the growth and spread of tumor cells, thereby extending patient survival.

Pemetinib is considered effective in patients with biliary tract cancer that has progressed after at least one prior treatment and for which there are no other authorized treatments. Patients can tolerate the side effects of medications if they require close monitoring and treatment. In a major study involving 108 patients with biliary tract cancer with abnormal FGFR2, pemetinib effectively shrank cancer lesions. Approximately 37% of patients experienced cancer shrinkage that lasted an average of eight months.

It is important to note, however, that pemetinib is currently only suitable for patients with cholangiocarcinoma whose disease has progressed after receiving at least one chemotherapy drug and for whom specific FGFR gene mutations are present in their tumors. Therefore, before using pemetinib, doctors often perform genetic testing to determine whether a patient is a candidate for treatment with the drug. As with any medicine, pemetinib may cause some adverse reactions, including nausea, vomiting, fatigue, loss of appetite, diarrhea, and numbness in the hands and feet. Therefore, during the use of pemetinib, doctors will closely monitor the patient's physical condition and make appropriate adjustments and treatments as needed.